|
|
Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MA, Carmona L; on behalf of the BIOBADASER 2.0 Study Group. |
| Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. |
| Ann Rheum Dis. 2011 Oct 13. [Epub ahead of print] - |
|
Descargar |
|
|
|
Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ; BIOBADASER Study Group |
| Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry |
| Med Clin (Barc). 2011 Nov 12;137(12):533-40. Epub 2011 Apr 22.. [Epub ahead of print] - |
|
Descargar |
|
|
|
Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, Gomez-Reino JJ; BIOBADASER Study Group; EMECAR Study Group |
| Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists |
| Semin Arthritis Rheum, 2011 Aug;41(1):71-80 - |
|
Descargar |
|
|
|
Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, Carmona L; BIOBADASER Study Group |
| Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review |
| Semin Arthritis Rheum. 2011 Dec;41(3):524-33.Feb;40(4):330-7 - |
|
Descargar |
|
|
|
Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, Perez-Pampin E, Gomez-Reino JJ, BIOBADASER 2.0 study group |
| Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0 |
| Rheumatology (Oxford), 2011 Jan;50(1):85-92 - |
|
Descargar |
|
|
|
García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ, Carmona L; BIOBADASER 2.0 Study Group |
| Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists |
| Ann Rheum Dis, 2010 Oct; 69 (10): 1751-5 - |
|
Descargar |
|
|
|
Descalzo MA, Carmona L, Grupo de estudio BIOBADASER |
| Biobadaser 2.0: análisis y tendencias en 2009 |
| Reumatol Clin, 2010; 6:240-3 - |
|
Descargar |
|
|
|
Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A |
| A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries |
| Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1. - |
|
Descargar |
|
|
|
Carmona L |
| Actualización de BIOBADASER |
| Reumatol Clin 2009; 05(Suppl 1):66-70 - |
|
Descargar |
|
|
|
Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups |
| Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy |
| Clin Exp Rheumatol 2009; 27(6):920-925 - |
|
Descargar |
|
|
|
Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC; Biobadaser group |
| Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience |
| Clin Exp Rheumatol, 2008 Sep-Oct;26(5):854-9 - |
|
Descargar |
|
|
|
Pérez-Zafrilla B, Descalzo MA, Carmona L, Grupo de estudio BIOBADASER. |
| Reacciones adversas relacionadas con la administración de los inhibidores del TNF. Análisis de un registro de terapias biológicas. BIOBADASER |
| Reumatol Clin. 2008;4(3):90-5 - |
|
Descargar |
|
|
|
Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo Ibanez T, Gomez-Reino JJ, Study Groups EB. |
| All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists. |
| Ann Rheum Dis. 2007 Feb 26; - |
|
Descargar |
|
|
|
Gomez-Reino JJ, Carmona L, Descalzo MA, Biobadaser Group. |
| Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. |
| Arthritis Rheum, 2007;57(5):756-61 - |
|
Descargar |
|
|
|
Descalzo MA. Comité científico de BIOBADASER y Grupo de estudio de BIOBADASER. |
| Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): informe de la situación, 26 de enero de 2006. |
| Reumatol Clin. 2007;3(1):4-20 - |
|
Descargar |
|
|
|
Gómez-Reino JJ, Carmona L. |
| Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. |
| Acta Reumatol Port. 2006;31(3);201-3 - |
|
Descargar |
|
|
|
Carmona L, Gomez-Reino JJ, BIOBADASER Group. |
| Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. |
| Arthritis Res Ther 2006 Apr 18;8(3):R72 - |
|
Descargar |
|
|
|
Gomez-Reino JJ, Carmona L, BIOBADASER Group. |
| Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. |
| Arthritis Res Ther 2006; 8:R29 - |
|
Descargar |
|
|
|
L Carmona, R González. |
| Espondiloartritis BIOBADASER. |
| Reumatol Clin 2005; 1(Suppl 1): S12-5. - |
|
Descargar |
|
|
|
L Carmona, JJ Gómez-Reino, V Rodríguez-Valverde, MD Montero, E Pascual-Gómez, E Martin Mola, L Carreño, M Figueroa, BIOBADASER Group. |
| Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. |
| Arthritis Rheum 2005; 52(6):1766-72 - |
|
Descargar |
|
|
|
L Carmona, JJ Gómez-Reino, R González, Grupo de Estudio BIOBADASER. |
| Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de situación a 14 de enero de 2005. |
| Reumatol Clin 2005; 1(2):95-111 - |
|
Descargar |
|
|
|
Comité Científico de BIOBADASER. |
| BIOBADASER: Informe de situación semestral. |
| Rev Esp Reumatol 2004; 31(8)479-91 - |
|
Descargar |
|
|
|
Carmona L. |
| Registro de acontecimientos adversos de terapias biológicas en enfermedades reumáticas: BIOBADASER. |
| Rev Esp Reumatol 2004 :31(4):210-3 - |
|
Descargar |
|
|
|
Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Comité Científico de BIOBADASER. |
| Treatment of rheumatoid arthritis with TNF inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. |
| Arthritis Rheum 2003; 48(8):2122-7 - |
|
Descargar |
|
|
|
Comité Científico de BIOBADASER. |
| BIOBADASER: Informe de situación semestral. |
| Rev Esp Reumatol 2003; 30(10)554-64 - |
|
Descargar |
|
|
|
Comité Científico de BIOBADASER. |
| BIOBADASER: Informe de situación semestral. |
| Rev Esp Reumatol 2003;30(3):119-23 - |
|
Descargar |
|
|
|
Comité Científico de BIOBADASER. |
| BIOBADASER: Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas. |
| Rev Esp Reumatol 2002;29(6):292-299 - |
|
Descargar |
English version